The Cancer Moonshot Task Force: Removing Bureaucratic Hurdles and Supporting Scientific Advances
Joe Biden (Archives)
18639

As the primary endpoint in cancer treatment clinical trials is all cause mortality, perhaps a PARADIGM SHIFT is needed. Rather than waging war on cancer, it may be more appropriate to wage war on “immunosenescence” (immune aging). This way, morbidity and mortality due to all causes can be addressed, and thereby, success assured.

See new HERV-K102 – AFP Immunosenescence Paradigm released Jan 15, 2016 in Discovery Medicine 20(112):379–391, 2015 by Dr. Marian Laderoute.

One clap, two clap, three clap, forty?

By clapping more or less, you can signal to us which stories really stand out.